ProCE Banner Activity

Podcast Pearls
Individualizing Care for Patients With Triple-Negative Breast Cancer

Slideset Download
Download this short slideset of key points from a podcast on current optimal approaches for the management of patients with TNBC.

Released: January 18, 2023

Share

Faculty

Mark D. Pegram

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Sara Tolaney

Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Gilead Sciences, Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Mark Pegram, MD: consultant/advisor/speaker: AstraZeneca/Daiichi Sankyo, Gilead Sciences, Roche/Genentech.

Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH: consultant/advisor: 4D Pharma, AstraZeneca, ARC Therapeutics, Athenex, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech/Roche, Gilead Sciences, Infinity Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana Therapeutics, Myovant, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zymeworks; steering committee: CytomX, Lilly, OncXerna; researcher (paid to institution): AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead Sciences, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate, Pfizer, Sanofi, Seattle Genetics.